Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with E
Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
---|---|---|---|---|---|---|---|
Q2 2022 | EDETATE DISODIUM | INTRAVENOUS | LIQUID | 0.05 %w/v | Correction | ||
Q3 2022 | EDETATE DISODIUM | INTRAVENOUS | LIQUID | 0.03 %w/v | Correction | ||
Q3 2022 | EDETATE TRISODIUM | INTRAVENOUS | INJECTION | 0.37 %w/v | Deletion | ||
Q2 2022 | EDETATE DISODIUM | TOPICAL | CREAM, AUGMENTED | 0.10 %w/w | MDE Replacement | ||
Q3 2022 | EDETATE DISODIUM | TOPICAL | CREAM, AUGMENTED | 2mg | MDE Replacement | ||
Q2 2022 | ETHYL VANILLIN | ORAL | PASTE | 0.22 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | ETHYL VANILLIN | ORAL | PASTE | 7mg | MDE Replacement | ||
Q2 2022 | ETHYLCELLULOSE AQUEOUS DISPERSION TYPE B | ORAL | GRANULE, FOR SUSPENSION | 10.62 mg | MDE Replacement | ||
Q3 2022 | ETHYLCELLULOSE AQUEOUS DISPERSION TYPE B | ORAL | GRANULE, FOR SUSPENSION | 21mg | MDE Replacement | ||
Q2 2022 | ETHYLPARABEN | ORAL | POWDER, FOR SOLUTION | 0.66 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | ETHYLPARABEN | ORAL | POWDER, FOR SOLUTION | 13mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 1, 2022
Database Last Updated: July 18, 2022